FDA approves Gilead’s HIV PrEP drug Descovy

This article was originally published here

Descovy for PrEP has been approved to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents weighing minimum 35kg who are HIV-negative and at-risk for

The post FDA approves Gilead’s HIV PrEP drug Descovy appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply